Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple...

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Pretreated relapsed/refractory multiple myeloma (RRMM) presents a significant clinical challenge with limited therapeutic options.
• There is a critical need for novel, safe, and effective treatments that offer durable responses in RRMM patients.

Purpose of the Study:

• To evaluate the efficacy and safety of magrolimab in combination with daratumumab, pomalidomide/dexamethasone, or carfilzomib/dexamethasone in patients with RRMM.
• To determine the objective response rate (ORR) as the primary efficacy endpoint for these magrolimab-based regimens.

Main Methods:

• A Phase 2 study was conducted involving RRMM patients treated with magrolimab combined with either daratumumab, pomalidomide/dexamethasone, or carfilzomib/dexamethasone.
• The primary efficacy endpoint assessed was the objective response rate (ORR). Safety was evaluated through adverse event (AE) monitoring.

Main Results:

• Objective response rates (ORR) were observed as 14.3% for magrolimab plus daratumumab, 20.0% for magrolimab plus pomalidomide/dexamethasone, and 36.4% for magrolimab plus carfilzomib/dexamethasone.
• Dose-limiting toxicities included febrile neutropenia and infusion-related reactions. Grade ≥ 3 magrolimab-related adverse events occurred in 60-64% of patients across combinations. Two deaths were AE-related, but not attributed to magrolimab.

Conclusions:

• The combination of magrolimab with carfilzomib/dexamethasone demonstrated a higher ORR compared to other regimens in this Phase 2 study.
• Due to early study termination, comprehensive clinical insights into magrolimab combinations for RRMM remain limited. Further investigation is warranted.